Arrivent Biopharma received FDA IND clearance for ARR-002 (AV-P138-ADC), marking a step toward initiating a Phase I trial focused first on ovarian and endometrial cancers and expanding across solid tumors. The company’s ADC targets MUC16 and NaPi2b. In parallel, Harbour Biomed secured IND clearance for HBM-7004, a B7H4 x CD3 bispecific developed using its HBICE platform, with a planned Phase I trial for advanced solid tumors. Harbour said preclinical work showed intratumor B7H4-dependent T-cell activation. Both actions add early clinical momentum to manufacturers building next-generation antibody modalities aimed at expanding solid tumor reach.